UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

~~FORM~~Form 6-K

~~REPORT~~Report OFof ~~FOREIGN~~Foreign ~~PRIVATE~~Private ~~ISSUER~~Issuer

~~PURSUANT~~Pursuant TOto ~~RULE~~Rule 13a-16 ORor 15d-16

~~UNDER~~under ~~THE~~the ~~SECURITIES~~Securities ~~EXCHANGE~~Exchange ~~ACT~~Act OFof 1934

For the month of January 2026 (Report No. 2)

Commission File Number: 001-42796

~~Nasus~~NASUS ~~Pharma~~PHARMA Ltd.

(Translation of registrant’s name into English)

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive ~~office~~offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

CONTENTS

~~Press~~Attached ~~Release~~hereto and incorporated herein are the Notice of Meeting, Proxy Statement and Proxy Card for the Special General Meeting of Shareholders of Nasus Pharma Ltd. (the “Company”) to be held on Thursday, March 5, 2026 (the “Meeting”).

OnOnly ~~January~~shareholders ~~20,~~of ~~2026,~~record ~~Nasus~~who ~~Pharma~~hold ~~Ltd.~~ordinary ~~(the~~shares, ~~“Company”)~~no ~~issued~~par avalue, ~~press~~of ~~release~~the ~~titled~~Company ~~“Nasus~~at ~~Pharma~~the ~~Announces~~close ~~Positive Interim Results from Phase 2 Clinical Study~~ of ~~NS002~~business ~~Intranasal~~on ~~Epinephrine Powder~~Monday,” aFebruary ~~copy~~9, of2026 ~~which~~will be isentitled ~~furnished~~to asnotice ~~Exhibit~~of ~~99.1~~ and to ~~this~~vote ~~Report~~at ofthe ~~Foreign~~Meeting ~~Private~~and ~~Issuer~~any onpostponements ~~Form~~or ~~6-K~~adjournments thereof.

~~Investor~~Copies ~~Presentation~~of the Notice of Special General Meeting, Proxy Statement and Form of Proxy Card for the Meeting are furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively.

~~On January 20, 2026, the Company made available an updated corporate presentation on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.~~2 ~~to this Report of Foreign Private Issuer on Form 6-K.~~

EXHIBIT INDEX

Exhibits No.
99.1		Notice for the Special General Meeting of Shareholders to be held on March 5, 2026.
99.2		Proxy Statement for the Special General Meeting of Shareholders to be held on March 5, 2026.
99.3		Form of Proxy Card for the Special General Meeting of Shareholders to be held on March 5, 2026.

Exhibit No.		Description
99.1		Press Release issued on January 20, 2026 by Nasus Pharma Ltd. titled “Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder”
99.2		Corporate Presentation, dated January 2026.

~~SIGNATURE~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
	Nasus Pharma Ltd.
Date: January 20, 2026	By:	/s/ Dan Teleman
Date: January 29, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

Filing Compare · Nasus Pharma Ltd